One explanation is that survival of those primitive CML cells were not dependent on BCR-ABL kinase activity so that therapies that biochemically target BCR-ABL could not eliminate CML stem cells [4,5]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.